Our exhibitors


Eisai is derived from the Japanese word for ‘health product’ and, here at Eisai, we discover, develop and market innovative, high-quality medicines throughout the world.

In Australia and New Zealand, Neurology and Oncology are our primary specialty areas.

For more information about Eisai, or our products, please choose one of the following:
For Australia: visit www.eisai.com.au or email Contact_Australia@eisai.net
For New Zealand: visit www.eisai.co.nz or email Contact_NewZealand@eisai.net


GSK is a global biopharma company with the ambition and purpose to unite science, technology and talent to get ahead of disease together.

We aim to positively impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance.

We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.


Haloguard is a Christchurch based company providing a cutting edge , wearable personal safety alarm throughout Australasia.

The haloguard App and wearable device work together seamlessly by sending an immediate alarm to designated emergency contacts, with the precise GPS location and live stream audio. This real time information enables the designated contacts to make informed and immediate decisions on the assistance required.

Our mission is simple: We believe everyone deserves to feel safe, connected and protected. HaloGuard empowers people of all ages to live and work confidently no matter where life takes them.

Nutricia Souvenaid Danone

Building on 125 years of research, innovation and care, Nutricia pioneers medical nutrition that helps enable life-changing and life-saving health outcomes, so that people can live their life to its fullest.

Nutricia supports healthy growth and development in early life and plays its part addressing some of the world’s biggest health challenges from birth through to old age. The Nutricia portfolio includes a wide range of nutritional solutions for pre-term birth, faltering growth, food allergy, rare metabolic diseases, age-related conditions and chronic disease, such as frailty, cancer, stroke and early Alzheimer’s disease.

As part of Danone, Nutricia embraces the company’s “One Planet. One Health” frame of action reflecting that the health of people and the health of the planet are interconnected and therefore seeks to protect and nourish both.

Souvenaid, launched in 2013 in Australia, is a medical drink formulated to nutritionally support memory function in patients with early Alzheimer’s Disease when taken daily for at least 6 months. Over time, Alzheimer’s disease causes a loss of synapses or connections in the brain. Souvenaid contains a unique combination of nutrients formulated to support the growth of brain connections. Backed by 20 years of research, Souvenaid is proven to slow memory and cognitive decline by 60% in an early stage of Alzheimer’s disease known as mild cognitive impairment when taken daily for 3 years.

Reid Technology

Reid Technology is a leading New Zealand provider of assistive technologies for people with hearing, visual or cognitive impairment. On stand 7 we will be exhibiting the following products;

  • Abilia (Sweden) - Daily organiser touch screens
  • Bellman & Symfon (Sweden) - Alerting systems for hearing impaired people
  • Oricom (Australia) - Big button amplified home telephones
  • Speaksee (Holland) - Speech to text with language translation


STADA Australia is a speciality prescription pharmaceutical and consumer healthcare company.

Part of a global group, STADA Arzneimittel AG, the company sells its products in approximately 120 countries worldwide.

Since 2016, STADA has provided prescription products in Australia and New Zealand, for both chronic and serious medical conditions, with a particular focus on the treatment of Parkinson’s disease. The STADA Nurse Advisor Service has supported this work by partnering with all relevant healthcare professionals, providing a high-quality service for patients and their families.

Building on this success, STADA Australia is currently expanding into new therapeutic areas with a clear purpose of caring for people‘s health as a trusted partner.